Brief: Newron Pharmaceuticals re-submits US NDA for Xadago
22/09/2016 06:00
Sept 22 (Reuters) - Newron Pharmaceuticals Spa NWRN.S :
* Re-submits US New Drug Application for Xadago (safinamide)
* As a class 2 resubmission, FDA is expected to complete its
review of re-submission within 6 months of acceptance
Source text for Eikon: ID:nTEN0x0f8a
Further company coverage: NWRN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study